Hesperos Inc.'s human-on-a-chip in vitro model for the first time successfully predicted human response to two drugs. The multi-organ model provided new insight into the drugs' cardiotoxic effects in a study published in Nature Scientific Reports. The Orlando, Fla.-based company also recently demonstrated that its model could simultaneously measure cancer drug efficacy and off-target toxicity without animal models or human testing.